Clinical Trials Search at Vanderbilt-Ingram Cancer Center
A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-Line Advanced Renal Cell Carcinoma (RCC)
Kidney (Renal Cell)
Kidney (Renal Cell)
Kidney (Renal Cell)
II
Rini, Brian
NCT07188896
VICCURO24517
A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK4/6 Inhibitor Therapy (OPERA-01)
Breast
Breast
Breast
III
Abramson, Vandana
NCT06016738
VICC-DTBRE23292
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-Risk Primary or Secondary Myelofibrosis
Leukemia
Leukemia
Leukemia
I/II
Kishtagari, Ashwin
NCT04176198
VICC-DTHEM23002P
A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer
Multiple Cancer Types
Esophageal,
Gastric/Gastroesophageal
III
Gibson, Mike
NCT06532006
VICCGI24578
Evaluation of Digoxin for Relapsed non-WNT, non-SHH Medulloblastoma (Phase 2 Study)
Multiple Cancer Types
Neuro-Oncology,
Pediatrics
II
Esbenshade, Adam
NCT06701812
VICCPED24621
Expanded Access Protocol (EAP) For Subjects Receiving Lisocabtagene Maraleucel That Is Nonconforming For Commercial Release
Lymphoma
Lymphoma
Lymphoma
N/A
Oluwole, Olalekan
NCT04400591
VICCCTT24506
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Miscellaneous
Miscellaneous
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to:
* Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan
* Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan
* Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan
* Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan
* Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan
* Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan
Miscellaneous
I/II
Cardin, Dana
NCT04657068
VICCGIP25035
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-Cell Lymphoma (ALPHA3)
Lymphoma
Lymphoma
Lymphoma
II
Jallouk, Andrew
NCT06500273
VICC-DTCTT24008
A Phase II Non-Comparative Trial of Datopotamab Deruxtecan (Dato-DXd) or Trastuzumab Deruxtecan (T-DXd) in Patients with Metastatic HER2-Negative (HER2-Low or HER2-0) Breast Cancer After Progression on Prior Antibody Drug Conjugate Therapy (TRADE DXd)
Breast
Breast
Breast
II
Abramson, Vandana
NCT06533826
VICC-ITBRE23546
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Multiple Cancer Types
Pediatrics,
Sarcoma
III
Borinstein, Scott
NCT05235165
COGAOST2031
